stockchase picture

Compiling comments that experts make about stocks while on public TV.

Company Index

List by Company Name

List by Symbol

Abbott Labs Stock Symbol: ABT-N

Last Price Recorded: $40.8600 on 2014-10-20 01:14:01

Globe 200 day average
Google Discussions (view only)
yahoo discussion
Bloomberg
Date Signal Expert Opinion Price
2014-10-14 TOP PICK Brian Acker, CA

Spinning off another division. He loves the drug space, which is free of volatility. His model price is $45, a 10% upside.


Price:
$41.060
Subject:
AGRICULTURE, DIVIDEND & FIXED INCOME
Bias:
UNKNOWN
Owned:
Yes
2014-10-07 PAST TOP PICK Christine Poole

(A Top Pick Oct 29/13. Up 13.13%.) A diversified global healthcare company. They have 4 divisions including brand generics which is more focused on emerging markets. Also, have a nutritional business as well as a stents division along with the diagnostic division. Pays a dividend of about 2%.


Price:
$41.460
Subject:
NORTH AMERICAN - LARGE
Bias:
BULLISH
Owned:
Yes
2014-09-17 TOP PICK Brian Acker, CA

His model price is $48.91, a 14% upside. Saw that they are going to spin off another company, the gift that keeps on giving. He loves large-cap drug companies. Yield of 2.02%.


Price:
$43.380
Subject:
NORTH AMERICAN - LARGE
Bias:
BULLISH on US$
Owned:
Yes
2014-08-29 COMMENT Jennifer Radman

Doesn’t follow this one too closely. Recent reports indicate they are doing a lot of things to restart their growth.


Price:
$42.240
Subject:
US LARGE
Bias:
OPTIMISTIC
Owned:
No
2014-07-08 PAST TOP PICK Christine Poole

(Top Pick July 9/13, Up 20.37%) Prefers to stay with this part of the business after the spin out.  This is where the growth is.  They have branded generics which are a growth area in emerging markets.  The just made an acquisition to increase presence in Latin America where pharma should double in the next 5 years.


Price:
$41.050
Subject:
NORTH AMERICAN - LARGE
Bias:
OPTIMISTIC
Owned:
Yes
2014-04-09 DON'T BUY Stan Wong

This one has outperformed the health care sector over the last few years.  Sees a 15% growth rate on the dividend, but it is low compared to others.  Prefers PFE-N.


Price:
$37.630
Subject:
NORTH AMERICAN - LARGE & ETFs
Bias:
SELECTIVE
Owned:
No
2014-02-18 BUY Stuart Hinshelwood

Growth in large-cap pharmaceutical business is fairly anaemic. There are not a lot of great growth prospects. What he does like about this company is that they have a medical technology business, a nutritionals business as well as a traditional pharmaceutical business i.e. all the components of the healthcare sector. Feels there is some growth from an earnings perspective. (See Top Picks.)


Price:
$38.930
Subject:
US EQUITIES
Bias:
CAUTIOUS
Owned:
Yes
2014-02-07 BUY Michael Bowman

Is this a good time to get into health care stocks and what would you recommend? Likes Abbott Labs (ABT-N) very much. Spun off their pharmaceutical R&D business about 2 years ago and split themselves up into 4 different divisions. If looking at global healthcare companies, you can’t go wrong with something like Johnson & Johnson (JNJ-N). Products are cheap and they can easily raise costs. Also, likes Medtronics (MDT-N) which is a device manufacturer.


Price:
$37.180
Subject:
NORTH AMERICAN - LARGE & ETFs
Bias:
BULLISH
Owned:
Unknown
2014-02-04 PAST TOP PICK Christine Poole

(A Top Pick Feb 12/13. Up 7.44%.) Still likes this. Likes their branded pharmaceuticals division. Also, have diagnostics and nutritionals. Company increased their dividend by quite a large amount last quarter. Yield of about 2.5%. Trading at an attractive multiple.


Price:
$36.250
Subject:
NORTH AMERICAN - LARGE
Bias:
BULLISH
Owned:
Yes
2014-01-29 DON'T BUY Gordon Reid

Has really been falling. Results were a little mixed. Management was quite cautious and said the 2nd half was going to be a challenging time, partly because of difficult comparisons and partly because of the stronger US$. He just doesn’t see a catalyst and the price is a little too high for him.


Price:
$35.850
Subject:
US EQUITIES
Bias:
OPTIMISTIC
Owned:
No
2014-01-02 BUY Gordon Reid

A good stable company. Sold his holdings when they spun off their pharmaceutical division. They are now left with medical devices, nutritional business and their diagnostic business. Have a wonderful record of growing dividends over the years. Very steady and he feels it is underappreciated.


Price:
$38.230
Subject:
US EQUITIES
Bias:
OPTIMISTIC
Owned:
No
2013-12-23 COMMENT Barry Schwartz

Sold his holdings a few months ago in order to look for other opportunities. Valuations are a little too excessive for him. He prefers to buy in the 12-13 times earnings range. Doesn’t see growth in this one.


Price:
$38.440
Subject:
NORTH AMERICAN - LARGE
Bias:
BULLISH
Owned:
No
2013-12-09 TOP PICK Gavin Graham

Spun off drug side.  It is medical devices and has been one of the most consistent growers over the last decade.  Reasonably priced, 2.5% yield.


Price:
$37.200
Subject:
GLOBAL & NORTH AMERICAN LARGE
Bias:
BULLISH
Owned:
Yes
2013-11-29 PAST TOP PICK Brian Acker, CA

(A Top Pick Nov 26/12. Up 24.63%.) There was a spin out of Abbvie (ABBV-N) from this company


Price:
$38.190
Subject:
NORTH AMERICAN - LARGE
Bias:
BULLISH
Owned:
No
2013-11-01 TOP PICK Stuart Hinshelwood

Bought this because he was looking to increase his exposure to healthcare. Not that expensive. Nice diverse portfolio. Good exposure, both in North America and outside. Could be $42 over 12 months.


Price:
$36.960
Subject:
US EQUITIES
Bias:
BULLISH
Owned:
Yes
Showing 1 to 15 of 85 entries
First Previous 1 2 3 4 5 Next Last

No Comments.


You must be logged in to comment.